Clinical Trial Update: Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating everolimus (RAD001) in children with chemotherapy-refractory progressive or recurrent low-grade gliomas has completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Glioma
• Low-grade Glioma

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Glioma, Low-grade Glioma | Phase 2 | Status: COMPLETED | Results posted: 2016-02-02